Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
N/A
1(25.0%)
4Total
Phase 2(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01416753Not ApplicableCompleted

Response Options to Blood Volume Monitoring in Fluid Overloaded Hemodialysis Patients

Role: lead

NCT00830297Phase 2Completed

Treat-to-target Trial of Basal Insulin in Post-transplant Hyperglycemia

Role: lead

NCT00828503Phase 2Unknown

Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients

Role: lead

NCT01346254Phase 2Completed

Glucose Control in Pre-Diabetic Renal Transplant Patients

Role: lead

All 4 trials loaded